CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


AbivertinibWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1030 HLCM051 Wiki 1.00
drug2319 Standard of Care Wiki 0.20

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.11
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.10
D012128 Respiratory Distress Syndrome, Adult NIH 0.09

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19

Study to assess the safety and efficacy of STI-5656 (Abivertinib Maleate) plus SOC versus SOC in subjects hospitalized with COVID-19

NCT04440007 Covid-19 Drug: Abivertinib Other: Standard of Care

Primary Outcomes

Description: Proportion of subjects alive and free of respiratory failure at Day 14

Measure: Proportion of subjects alive and free of respiratory failure at Day 14

Time: Randomization to Day 14

Secondary Outcomes

Description: Types, frequencies, and severities of adverse events and their relationships to STI-5656

Measure: Incidence of treatment-emergent adverse events (safety and tolerability of STI-5656)

Time: Randomization through study completion to 90 days

Description: Proportion of subjects alive and free of respiratory failure at Day 28

Measure: Proportion of subjects alive and free of respiratory failure at Day 28

Time: Randomization to Day 28

Description: Change in clinical status on a 0-8-point ordinal scale (lower score means better outcome; 0=uninfected, 8=dead)

Measure: Change in clinical status

Time: Randomization to Day 7, Day 14, and Day 28

Description: Proportion of subjects alive and discharged from ICU at Days 14 and 28

Measure: Discharge from ICU

Time: Randomization to Day 14 and Day 28

Description: Time from randomization to first occurrence of respiratory failure or death on study due to any cause up to Day 28

Measure: Time to respiratory failure or death

Time: Randomization to Day 28


No related HPO nodes (Using clinical trials)